| Efficacy of long-term interferon therapy in chronic hepatitis B patients with HBV genotype C. | |
| | |
MedLine Citation:
|
PMID: 12119559 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Infection with Hepatitis B virus (HBV) genotype C predominates in Japan. We analyzed the efficacy of interferon (IFN) alpha or beta in the treatment of chronic hepatitis B patients with HBV genotype C and the clinical predictors for therapeutic response. Forty-three genotype C-infected, chronic hepatitis B e antigen (HBeAg)-positive patients (32 men and 11 women with a mean age of 35.6+/-10.1 years) who had been treated with IFN therapy were retrospectively studied. The patients were classified into two treatment groups. Short-term therapy group was administered a 5-6 MU dose three times weekly for 4 weeks, and the long-term therapy group for 24 weeks. At the end of the follow-up period, 4 (15%) of 27 short-term therapy group patients and 6 (38%) of 16 long-term therapy group patients had normalized serum ALT levels and seroconversion of HBeAg to anti-HBe (p=0.137). Multivariate analysis for parameters most important for the efficacy of IFN therapy was performed using Cox proportional hazard models in order to investigate the association between baseline characteristics of patients and the response to IFN treatment. As a result, the p-values of IFN treatment group and sex were <0.05, and both factors can be recognized as independent significant factors (relative risk, 2.93 and 2.53; p=0.027 and 0.040, respectively). Furthermore, the cumulative rates of seroconversion of HBeAg to anti-HBe analyzed by the Kaplan-Meier method was significantly higher in the female group (p=0.015) and in the long-term IFN therapy group (p=0.0046). In summary, long-term IFN therapy may be more effective than short-term IFN therapy for patients with chronic HBV genotype C infection. |
| | |
Authors:
|
Takahisa Sakai; Katsuya Shiraki; Hidekazu Inoue; Hiroshi Okano; Masatoshi Deguchi; Kazushi Sugimoto; Shigeru Ohmori; Kazumoto Murata; Takeshi Nakano |
Related Documents
:
|
21835449 - Cryopreservation of immature equine oocytes, comparing a solid surface vitrification pr... 11354279 - Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogen... 16753449 - Single-blind, multicenter, placebo controlled, parallel study to assess the safety and ... 15336449 - Comparison of clinical outcome between patients continuing and discontinuing lamivudine... 16764659 - Biologic therapies for inflammatory eye disease. 2576629 - Lack of activity of zidovudine in aids-associated kaposi's sarcoma. 11253859 - Periorbital cellulitis secondary to conidiobolus incongruus. 7340429 - The management of cerebrospinal fluid shunt infections: a clinical experience. 22567409 - The memory metal minimal access cage: a new concept in lumbar interbody fusion-a prospe... |
Publication Detail:
|
Type: Comparative Study; Journal Article |
Journal Detail:
|
Title: International journal of molecular medicine Volume: 10 ISSN: 1107-3756 ISO Abbreviation: Int. J. Mol. Med. Publication Date: 2002 Aug |
Date Detail:
|
Created Date: 2002-07-16 Completed Date: 2003-01-22 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9810955 Medline TA: Int J Mol Med Country: Greece |
Other Details:
|
Languages: eng Pagination: 201-4 Citation Subset: IM |
Affiliation:
|
First Department of Internal Medicine, Mie University School of Medicine, Tsu, Mie 514-8507, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Alanine Transaminase / blood Antiviral Agents / therapeutic use* Biological Markers DNA, Viral / genetics Drug Administration Schedule Drug Evaluation Female Genotype Hepatitis B Antibodies / blood Hepatitis B e Antigens / blood Hepatitis B virus / genetics*, isolation & purification Hepatitis B, Chronic / drug therapy*, enzymology, virology Humans Interferon-alpha / therapeutic use* Interferon-beta / therapeutic use* Japan Life Tables Male Middle Aged Polymorphism, Restriction Fragment Length Retrospective Studies Sex Factors Time Factors Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antiviral Agents; 0/Biological Markers; 0/DNA, Viral; 0/Hepatitis B Antibodies; 0/Hepatitis B e Antigens; 0/Interferon-alpha; 77238-31-4/Interferon-beta; EC 2.6.1.2/Alanine Transaminase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Resveratrol, a chemopreventive agent, disrupts the cell cycle control of human SW480 colorectal tumo...
Next Document: Telomerase activity and hTERT mRNA in development and progression of adenoma to colorectal cancer.